Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Investigation of a vaccine against Cryptosporidium parvum using an attenuated Salmonella vector
FY 2019-20
Summary
"Cryptosporidium parvum is a waterborne human pathogen of significant concern. The ingestion of as few as 10 oocysts can lead to cryptosporidiosis in healthy persons, a diarrheal disease that can result in severe dehydration and even death in immunocompromised patients. Currently, there are very limited options to prevent or treat cryptosporidiosis. The aim of this project is to develop a potential vaccine candidate against C. parvum. A fusion protein comprised of Cp15 and Cp23 (Cp15-23) was chosen as the target antigen for this vaccine as it was previously shown to induce partial protection against C. parvum in the form of a DNA vaccine. A highly attenuated S. enterica Typhimurium (YS1646) will be used as the vector to deliver Cp15-23 orally (PO) because of its ability to locally invade the intestinal epithelium, the same site targeted by C. parvum sporozoites. It is hypothesized that the Cp15-23 fusion protein expressed by a Salmonella-vectored vaccine will prove to be immunogenic and protective in C57BL/6 mice, with or without an additional intramuscular (IM) boost of the same antigen. Functional constructs will be made to express Cp15-23 in Salmonella and in E. coli. Once successfully produced, we will evaluate the systemic and mucosal immunogenicity of the Cp15-23 fusion protein in C57BL/6 mice administered either PO alone or in a multi-modality schedule (PO+IM). We will then evaluate the protective efficacy of the Cp15-23 Salmonella-vectored vaccine in an oocyst challenge model using IFN-gamma-receptor knockout mice, mice that are highly susceptible to C. parvum. We hope to demonstrate that YS1646 expressing Cp15-23 is immunogenic and protective and has potential as a vaccine candidate against C. parvum. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428781
Name
Du Iris Y
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of a vaccine against Cryptosporidium parvum using an attenuated Salmonella vector
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cryptosporidiosis; Cryptosporidium Parvum; Immunity; Live Attenuated Vaccine; Salmonella Typhimurium; Vaccine
Abstract
"<em>Cryptosporidium parvum </em>is a waterborne human pathogen of significant concern. The ingestion of as few as 10 oocysts can lead to cryptosporidiosis in healthy persons, a diarrheal disease that can result in severe dehydration and even death in immunocompromised patients. Currently, there are very limited options to prevent or treat cryptosporidiosis. The aim of this project is to develop a potential vaccine candidate against <em>C. parvum</em>. A fusion protein comprised of Cp15 and Cp23 (Cp15-23) was chosen as the target antigen for this vaccine as it was previously shown to induce partial protection against <em>C. parvum</em> in the form of a DNA vaccine. A highly attenuated <em>S. enterica</em> Typhimurium (YS1646) will be used as the vector to deliver Cp15-23 orally (PO) because of its ability to locally invade the intestinal epithelium, the same site targeted by <em>C. parvum </em>sporozoites. It is hypothesized that the Cp15-23 fusion protein expressed by a <em>Salmonella</em>-vectored vaccine will prove to be immunogenic and protective in C57BL/6 mice, with or without an additional intramuscular (IM) boost of the same antigen. Functional constructs will be made to express Cp15-23 in <em>Salmonella</em> and in <em>E. coli</em>. Once successfully produced, we will evaluate the systemic and mucosal immunogenicity of the Cp15-23 fusion protein in C57BL/6 mice administered either PO alone or in a multi-modality schedule (PO+IM). We will then evaluate the protective efficacy of the Cp15-23 <em>Salmonella</em>-vectored vaccine in an oocyst challenge model using IFN-gamma-receptor knockout mice, mice that are highly susceptible to <em>C. parvum</em>. We hope to demonstrate that YS1646 expressing Cp15-23 is immunogenic and protective and has potential as a vaccine candidate against <em>C. parvum</em>. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Du, Iris Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~